https://arab.news/9e8c2
- Warning comes amid fears that new, India variant could become dominant
- Virologist: “We’re still early on in the lifetime of this virus as a human pathogen”
LONDON: Humanity is engaged in an “arms race” with the coronavirus Sars-CoV-2, and its capacity to adapt and evolve remains unknown and should not be underestimated, scientists have warned.
“I think it’d be a brave person to say that the virus is nearing the end of its evolutionary route and can’t go any further,” Prof. Deenan Pillay, a virologist at University College London, told The Independent.
“We’re still early on in the lifetime of this virus as a human pathogen. It normally takes many years for viruses, once they cross the species barrier, to really optimize themselves to be able to replicate well within humans.”
Pillay’s warning comes amid fears that a new strain of Sars-CoV-2, known as the India variant — which has caused a surge in the number of cases of COVID-19 — could become a dominant global strain in the coming weeks.
The India variant is known to carry two mutations that could reduce the efficacy of a number of COVID-19 vaccines.
Whilst that has not yet occurred, the nature and speed at which the virus has mutated thus far, including in the form of the South African and UK variants, has caused alarm among the scientific community that the positive impact of vaccine rollouts could be undone in the near future.
Specifically, scientists worry about Sars-CoV-2’s ability to alter spike proteins, used to attach onto human cells, through mutations.
The spike proteins, referred to by Pillay as “keys” to entering human receptor cells, are the mechanism through which most of the world’s successful COVID-19 vaccines look to attack the virus, by training various immune system responses to identify them.
One such mutation, E484K, has been found in the South Africa and UK variants. The India variant carries a similar mutation, E484Q.
The fear is that by altering their proteins, these variants could render them less visible to the immune system of vaccinated people, making it harder to ward off infection.
Aris Katzourakis, professor of evolution and genomics at Oxford University, said beyond altering the spike protein, mutations such as E484K could “unlock a whole load of other mutations elsewhere in the spike” that have not yet been identified by scientists, with unknown repercussions for the severity of the virus.
“E484K took about 12 months before it became something we cared about. Presumably, 12 months from now, there’ll be another one or two that are just as important,” he told The Independent.
Prof. Stephen Griffin, a virologist at Leeds University, said he believes that rather than continue to mutate indefinitely, there “will be a limit on how far the spike protein can evolve. But I’m not sure we can accurately determine what that limit may be at this point.”